Optimize Financial Inc Buys New Stake in Kura Oncology, Inc. (NASDAQ:KURA)

Optimize Financial Inc purchased a new position in shares of Kura Oncology, Inc. (NASDAQ:KURA) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 11,447 shares of the company’s stock, valued at approximately $100,000.

Several other large investors have also recently added to or reduced their stakes in KURA. FMR LLC lifted its stake in shares of Kura Oncology by 26.1% during the third quarter. FMR LLC now owns 86,431 shares of the company’s stock worth $1,689,000 after purchasing an additional 17,913 shares in the last quarter. BNP Paribas Financial Markets lifted its position in Kura Oncology by 270.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,287 shares of the company’s stock worth $299,000 after acquiring an additional 11,158 shares in the last quarter. Jane Street Group LLC boosted its holdings in Kura Oncology by 36.7% in the 3rd quarter. Jane Street Group LLC now owns 126,085 shares of the company’s stock worth $2,464,000 after acquiring an additional 33,848 shares during the period. Barclays PLC boosted its holdings in Kura Oncology by 104.5% in the 3rd quarter. Barclays PLC now owns 165,484 shares of the company’s stock worth $3,234,000 after acquiring an additional 84,563 shares during the period. Finally, Geode Capital Management LLC grew its position in Kura Oncology by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock valued at $34,798,000 after acquiring an additional 41,535 shares in the last quarter.

Kura Oncology Stock Performance

Shares of NASDAQ KURA opened at $5.77 on Monday. Kura Oncology, Inc. has a 1 year low of $5.41 and a 1 year high of $23.48. The firm has a market cap of $465.96 million, a P/E ratio of -2.44 and a beta of 0.83. The stock has a fifty day moving average price of $7.36 and a two-hundred day moving average price of $10.80. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million. Research analysts forecast that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Insider Activity

In related news, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. The trade was a 5.32 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. This represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,729 shares of company stock worth $92,307. Corporate insiders own 5.50% of the company’s stock.

Wall Street Analysts Forecast Growth

KURA has been the subject of several analyst reports. Scotiabank decreased their target price on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 8th. BTIG Research cut shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. Wedbush reaffirmed an “outperform” rating and set a $36.00 target price on shares of Kura Oncology in a research report on Tuesday, April 8th. UBS Group reduced their price target on Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, March 6th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a report on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Kura Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.50.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.